Investigation of monoclonal antibody therapy with conventional and high-dose treatment: Current clinical trials
Open Access
- 1 October 2000
- journal article
- Published by Elsevier in Seminars in Hematology
- Vol. 37, 27-33
- https://doi.org/10.1016/s0037-1963(00)90057-x
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- The effect of Rituximab on patients with follicular and mantle-cell lymphomaAnnals of Oncology, 2000
- European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic LymphomaJournal of Clinical Oncology, 2000
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's LymphomasJournal of Clinical Oncology, 1999
- Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP ChemotherapyJournal of Clinical Oncology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998